Comment
doi: 10.1183/13993003.00173-2017.
Print 2017 Apr.
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Affiliations
- PMID: 28446561
- DOI: 10.1183/13993003.00173-2017
Item in Clipboard
Comment
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Eur Respir J.
.
Free article
No abstract available
Conflict of interest statement
Conflict of interest: None declared.
Comment in
-
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.Eur Respir J. 2017 Apr 26;49(4):1700317. doi: 10.1183/13993003.00317-2017. Print 2017 Apr. Eur Respir J. 2017. PMID: 28446562 No abstract available.
Comment on
-
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.Eur Respir J. 2017 Mar 22;49(3):1602308. doi: 10.1183/13993003.02308-2016. Print 2017 Mar. Eur Respir J. 2017. PMID: 28331043 Free PMC article.
Similar articles
-
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.Eur Respir J. 2017 Apr 26;49(4):1700317. doi: 10.1183/13993003.00317-2017. Print 2017 Apr. Eur Respir J. 2017. PMID: 28446562 No abstract available.
-
Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan.Clin Infect Dis. 2013 Apr;56(7):1054-5. doi: 10.1093/cid/cis978. Epub 2012 Nov 21. Clin Infect Dis. 2013. PMID: 23175554 No abstract available.
-
Fluoroquinolones resistance in multidrug-resistant tuberculosis in Pakistan and suitability of guidelines recommended standardized regimen.Int J Mycobacteriol. 2015 Sep;4(3):258-9. doi: 10.1016/j.ijmyco.2015.05.012. Epub 2015 Jun 21. Int J Mycobacteriol. 2015. PMID: 27649876 No abstract available.
-
Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness.Chest. 2015 Apr;147(4):1135-1143. doi: 10.1378/chest.14-1286. Chest. 2015. PMID: 25846529 Review.
-
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Korean J Intern Med. 2016 Jan;31(1):15-29. doi: 10.3904/kjim.2016.31.1.15. Epub 2015 Dec 28. Korean J Intern Med. 2016. PMID: 26767853 Free PMC article. Review.
Cited by
-
A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.J Antimicrob Chemother. 2021 Jan 19;76(2):423-429. doi: 10.1093/jac/dkaa420. J Antimicrob Chemother. 2021. PMID: 33089322 Free PMC article.
-
Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.Eur Respir J. 2018 May 24;51(5):1800109. doi: 10.1183/13993003.00109-2018. Print 2018 May. Eur Respir J. 2018. PMID: 29599189 Free PMC article. No abstract available.
-
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.BMJ Open. 2020 Jun 16;10(6):e035350. doi: 10.1136/bmjopen-2019-035350. BMJ Open. 2020. PMID: 32554740 Free PMC article.
-
Therapeutic drug monitoring in tuberculosis.Eur J Clin Pharmacol. 2024 Nov;80(11):1659-1684. doi: 10.1007/s00228-024-03749-8. Epub 2024 Sep 6. Eur J Clin Pharmacol. 2024. PMID: 39240337 Review.
-
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Drugs. 2019. PMID: 30617959 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
